MapLight’s schizophrenia pill hits primary endpoint but falls short of challenging BMS’s Cobenfy

MapLight Therapeutics reported results from its Phase 2 ZEPHYR trial of the oral muscarinic agonist ML-007C-MA in schizophrenia.

The trial met its primary endpoint, showing a statistically significant 4.5‑point reduction in PANSS total score versus placebo after five weeks in the modified intent‑to‑treat group.

However, the once‑daily dosing arm did not achieve its endpoint, and the drug did not deliver the “home run” efficacy that would threaten Bristol Myers Squibb’s already approved Cobenfy, which offers a fasting‑free regimen and a shorter titration.

Analysts at Jefferies said the results are encouraging but unlikely to shift market share, leaving BMS’s Cobenfy as the dominant muscarinic agonist for schizophrenia.